Free Trial
NASDAQ:EGRX

Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis

Eagle Pharmaceuticals logo
$1.90 0.00 (0.00%)
As of 05/29/2025 02:35 PM Eastern

About Eagle Pharmaceuticals Stock (NASDAQ:EGRX)

Key Stats

Today's Range
$1.65
$1.90
50-Day Range
$0.88
$2.00
52-Week Range
$1.50
$2.13
Volume
2,766 shs
Average Volume
10,208 shs
Market Capitalization
$24.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Receive EGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EGRX Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Eagle Pharmaceuticals to Delist from Nasdaq
Eagle Pharmaceuticals Appoints New CFO Amid Leadership Change
See More Headlines

EGRX Stock Analysis - Frequently Asked Questions

Eagle Pharmaceuticals' stock was trading at $0.50 on January 1st, 2025. Since then, EGRX stock has increased by 280.0% and is now trading at $1.90.
View the best growth stocks for 2025 here
.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 EPS for the quarter, beating the consensus estimate of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to analyst estimates of $46.70 million.

Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eagle Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Exxon Mobil (XOM), Advanced Micro Devices (AMD) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/09/2021
Today
5/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EGRX
Fax
N/A
Employees
100
Year Founded
2007

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$257.55 million
Cash Flow
$4.75 per share
Price / Cash Flow
0.40
Price / Book
N/A

Miscellaneous

Free Float
9,234,000
Market Cap
$24.68 million
Optionable
No Data
Beta
0.83

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:EGRX) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners